Victoria Socha

DocwireNews

Among patients with end-stage kidney disease (ESKD) receiving maintenance dialysis, sarcopenia is a frequent, yet under-recognized, complication. Wannasit Wathanavasin, MSc, and colleagues in Thailand conducted a systematic review and meta-analysis designed to assess the global prevalence of sarcopenia and examine whether the condition has an impact on clinical outcomes, particularly cardiovascular events and mortality in dialysis patients.Results of the study were reported during a poster session at the American Society of Nephrology Kidney Week 2022. The poster was titled The Prevalence of Sarcopenia and Its Impact on CV Events and Mortality Among ESKD Patients on Dialysis: A Systematic Review and Meta-Analysis.Eligible studies were identified via searches in PubMed, Scopus, and Cochrane Central Register of Controlled Trials through March 31, 2022. Cross-sectional and cohort studies that reported the prevalence of sarcopenia were included. Other outcomes of interest were low muscle mass and low muscle strength, as well as adverse events, including cardiovascular events and death.The pooled prevalence rate was calculated using the random-effects model. Associations between sarcopenia and clinical outcomes were expressed as odds ratio (OR) and 95% CI. The presence of heterogeneity was measured using Cochran&rsquo;s Q statistic and I2 test. Funnel plot and Egger&rsquo;s test also tested publication bias.The meta-analysis included 41 studies representing 7576 patients. The pooled prevalence of sarcopenia in patients on dialysis was 25.6% (95% CI, 22.1%-29.4%). Among various diagnostic criteria, the highest prevalence was found in the Asian Working Group for Sarcopenia 2019 criteria (36.9%; 95% CI, 30.4%-44.2%).There was a significant association between sarcopenia and higher mortality risk (adjusted OR [aOR], 1.83; 95% CI, 1.40-2.39) and cardiovascular events (aOR, 3.80; 95% CI, 1.79-8.09). There were independent associations between both low muscle mass and low muscle strength and increased risk of mortality in dialysis patients (OR, 1.71; 95% CI, 1.20-2.44 and OR, 2.15; 95% CI, 1.15-3.07, respectively).In conclusion, the researchers said, &ldquo;This meta-analysis revealed that sarcopenia was highly prevalent among dialysis patients and shown to be an important predictor of cardiovascular events and mortality. Future intervention research to alleviate this burden of disease in dialysis patients is needed.&rdquo;Source: Wathanavasin W, Banjongjit A, Avihingsanon Y, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. The prevalence of sarcopenia and its impact on CV events and mortality among ESKD patients on dialysis: a systematic review and meta-analysis. TH-PO790. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 3, 2022; Orlando, Florida.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Sarcopenia Prevalence and Adverse Cardiovascular Events

ASN Kidney Week 2022

Among patients with end-stage kidney disease (ESKD) receiving maintenance dialysis, sarcopenia is a frequent, yet under-recognized, complication. Wannasit Wathanavasin, MSc, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe